With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech
→ Another CEO opportunity has presented itself for James Scibetta, the chief executive of Maverick Therapeutics when Takeda ponied up $525 million in March to buy its T cell collaborator and integrate the staff into the R&D unit. Scibetta has signed on as CEO of antibody startup ImmuneID, co-founded and chaired by Longwood Fund’s Christoph Westphal with tech coming from Stephen Elledge’s lab at Harvard. So ends a fleeting CEO tenure for David Donabedian, who will stay close by as an advisor. Scibetta, the CFO and later president of Pacira Pharmaceuticals until he joined Maverick in 2017, steps forward to lead a biotech that’s chalked up $70 million in financing, including $50 million in a Series A this summer.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters